Palbociclib triggers cell cycle arrest by blocking retinoblastoma (Rb) phosphorylation through binding to the ATP binding site (8) and is approved for the treatment of hormonal receptor-positive, HER2- metastatic BC in combination with anti-hormonal therapy in Europe. Here, ERBB2 is linked to breast cancer.